Abstract
Giant cell arteritis (GCA) or Horton’s disease is a systemic granulomatous vasculitis of medium- and large-sized arteries. This is an antigen-driven disease with local T-cell and macrophage activation in the vessel wall and with an important role of proinflammatory cytokines. GCA is also called “temporal arteritis” because it involves often the superficial temporal arteries. The condition affects especially the extracranial branches of the carotid artery, but recently, GCA has been recognised to also affect limb arteries and the aorta with high prevalence.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Kesten F, Aschwanden M, Gubser P, Glatz K, Daikeler T, Hess C. Giant cell arteritis – a changing entity. Swiss Med Wkly. 2011;28:141.
Borchers AT, Gershwin ME. Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun Rev. 2012;11(6-7):A544.
Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 2009;61(10):1454–61.
Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis [review]. N Engl J Med. 2002;347:261–71.
Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med. 2003;139:505–15.
Assie C, Janvresse A, Plissonier D, Levesque H, Marie I. Long-term follow-up of upper and lower extremity vasculitis related to giant cell arteritis: a series of 36 patients. Medicine (Baltimore). 2011;90:40–51.
Kermani TA, Matteson EL, Hunter GC, Warrington KJ. Symptomatic lower extremity vasculitis in giant cell arteritis: a case series. J Rheumatol. 2009;36:2277–83.
Kermani TA, Warrington KJ. Lower extremity vasculitis in polymyalgia rheumatica and giant cell arteritis. Curr Opin Rheumatol. 2011;23(1):38–42. doi:10.1097/BOR.0b013e3283410072.
Klein RG, Campbell RJ, Hunder GG, Carney JA. Skip lesions in temporal arteritis. Mayo Clin Proc. 1976;51:504–10.
Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, Fulcher J, Hollywood J, Hutchings A, James P, Kyle V, Nott J, Power M, Samanta A, BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594–7.
Gonzalez-Gay M. The diagnosis and management of patients with giant cell arteritis. J Rheumatol. 2005;32:1186–8.
Unizony SH, Dasgupta B, Fisheleva E, Rowell L, Schett G, Spiera R, Zwerina J, Harari O, Stone JH. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol. 2013;2013:912562. doi:10.1155/2013/912562. Epub 2013 Apr 7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Wien
About this chapter
Cite this chapter
Lecerf, P. (2015). Giant Cell Arteritis. In: Téot, L., Meaume, S., Akita, S., Ennis, W.J., del Marmol, V. (eds) Skin Necrosis. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1241-0_18
Download citation
DOI: https://doi.org/10.1007/978-3-7091-1241-0_18
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-1240-3
Online ISBN: 978-3-7091-1241-0
eBook Packages: MedicineMedicine (R0)